Literature DB >> 25304791

Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.

Lara Hathout1, Michael R Folkert1, Marisa A Kollmeier1, Yoshiya Yamada1, Gil'ad N Cohen2, Michael J Zelefsky3.   

Abstract

PURPOSE: To identify an anatomic structure predictive for acute (AUT) and late (LUT) urinary toxicity in patients with prostate cancer treated with low-dose-rate brachytherapy (LDR) with or without external beam radiation therapy (EBRT). METHODS AND MATERIALS: From July 2002 to January 2013, 927 patients with prostate cancer (median age, 66 years) underwent LDR brachytherapy with Iodine 125 (n=753) or Palladium 103 (n=174) as definitive treatment (n=478) and as a boost (n=449) followed by supplemental EBRT (median dose, 50.4 Gy). Structures contoured on the computed tomographic (CT) scan on day 0 after implantation included prostate, urethra, bladder, and the bladder neck, defined as 5 mm around the urethra between the catheter balloon and the prostatic urethra. AUT and LUT were assessed with the Common Terminology Criteria for Adverse Events, version4. Clinical and dosimetric factors associated with AUT and LUT were analyzed with Cox regression and receiver operating characteristic analysis to calculate area under the receiver operator curve (ROC) (AUC).
RESULTS: Grade ≥2 AUT and grade ≥2 LUT occurred in 520 patients (56%) and 154 patients (20%), respectively. No grade 4 toxicities were observed. Bladder neck D2cc retained a significant association with AUT (hazard ratio [HR], 1.03; 95% confidence interval [CI], 1.03-1.04; P<.0001) and LUT (HR, 1.01; 95% CI, 1.00-1.03; P=.014) on multivariable analysis. In a comparison of bladder neck with the standard dosimetric variables by use of ROC analysis (prostate V100 >90%, D90 >100%, V150 >60%, urethra D20 >130%), bladder neck D2cc >50% was shown to have the strongest prognostic power for AUT (AUC, 0.697; P<.0001) and LUT (AUC, 0.620; P<.001).
CONCLUSIONS: Bladder neck D2cc >50% was the strongest predictor for grade ≥2 AUT and LUT in patients treated with LDR brachytherapy. These data support inclusion of bladder neck constraints into brachytherapy planning to decrease urinary toxicity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25304791      PMCID: PMC5705020          DOI: 10.1016/j.ijrobp.2014.06.031

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  31 in total

1.  Is there a relation between the radiation dose to the different sub-segments of the lower urinary tract and urinary morbidity after brachytherapy of the prostate with I-125 seeds?

Authors:  Marcel J Steggerda; Thelma Witteveen; Ferrie van den Boom; Luc M F Moonen
Journal:  Radiother Oncol       Date:  2013-09-20       Impact factor: 6.280

2.  American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy.

Authors:  Brian J Davis; Eric M Horwitz; W Robert Lee; Juanita M Crook; Richard G Stock; Gregory S Merrick; Wayne M Butler; Peter D Grimm; Nelson N Stone; Louis Potters; Anthony L Zietman; Michael J Zelefsky
Journal:  Brachytherapy       Date:  2012 Jan-Feb       Impact factor: 2.362

3.  Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.

Authors:  Daniel E Spratt; Zachary S Zumsteg; Pirus Ghadjar; Marisa A Kollmeier; Xin Pei; Gilad Cohen; William Polkinghorn; Yoshiya Yamada; Michael J Zelefsky
Journal:  BJU Int       Date:  2014-01-22       Impact factor: 5.588

4.  Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.

Authors:  Peter J Hoskin; Ana M Rojas; Peter J Bownes; Gerry J Lowe; Peter J Ostler; Linda Bryant
Journal:  Radiother Oncol       Date:  2012-02-16       Impact factor: 6.280

5.  A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.

Authors:  Zachary S Zumsteg; Daniel E Spratt; Isaac Pei; Zhigang Zhang; Yoshiya Yamada; Marisa Kollmeier; Michael J Zelefsky
Journal:  Eur Urol       Date:  2013-03-23       Impact factor: 20.096

6.  A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer.

Authors:  Marisa A Kollmeier; Xin Pei; Ece Algur; Yoshiya Yamada; Brett W Cox; Gil'ad N Cohen; Marco Zaider; Michael J Zelefsky
Journal:  Brachytherapy       Date:  2011-12-20       Impact factor: 2.362

7.  The dosimetry of prostate brachytherapy-induced urethral strictures.

Authors:  Gregory S Merrick; Wayne M Butler; Bryan G Tollenaar; Robert W Galbreath; Jonathan H Lief
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

8.  Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.

Authors:  Zachariah A Allen; Gregory S Merrick; Wayne M Butler; Kent E Wallner; Brian Kurko; Richard L Anderson; Brian C Murray; Robert W Galbreath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

9.  Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features.

Authors:  Michael Dattoli; Kent Wallner; Lawrence True; Jennifer Cash; Richard Sorace
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

10.  Dosimetric analysis of radiation therapy oncology group 0321: the importance of urethral dose.

Authors:  I-Chow Hsu; Daniel Hunt; William Straube; Jean Pouliot; Adam Cunha; Devan Krishnamurthy; Howard Sandler
Journal:  Pract Radiat Oncol       Date:  2013-03-29
View more
  23 in total

1.  Favorable long-term toxicity for salvage low-dose rate prostate brachytherapy for recurrent prostate cancer after external beam radiotherapy from a phase II prospective trial (NRG Oncology/RTOG 0526).

Authors:  Randall J Brenneman; Edward Soffen; Hiram A Gay; Peter F Orio; John P Christodouleas; John C Baumann; Brian C Baumann
Journal:  Transl Androl Urol       Date:  2019-07

2.  Tensor Regression-based Model to Investigate Heterogeneous Spatial Radiosensitivity After I-125 Seed Implantation for Prostate Cancer.

Authors:  Kazuma Kobayashi; Naoya Murakami; Kana Takahashi; Koji Inaba; Hiroshi Igaki; Ryuji Hamamoto; Jun Itami
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

3.  Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy.

Authors:  Adam Ferro; Hee Joon Bae; Gayane Yenokyan; Yi Le; Todd McNutt; Omar Mian; Carol Gergis; Chloe Haviland; Theodore L DeWeese; Daniel Y Song
Journal:  Brachytherapy       Date:  2017-11-23       Impact factor: 2.362

4.  Prostate cancer treated with image-guided helical TomoTherapy® and image-guided LINAC-IMRT : Correlation between high-dose bladder volume, margin reduction, and genitourinary toxicity.

Authors:  Sonia Drozdz; Michael Schwedas; Henning Salz; Susan Foller; Thomas G Wendt
Journal:  Strahlenther Onkol       Date:  2016-01-07       Impact factor: 3.621

5.  Radiation safety of receptive anal intercourse with prostate cancer patients treated with low-dose-rate brachytherapy.

Authors:  Nicola J Nasser; Gil'ad N Cohen; Lawrence T Dauer; Michael J Zelefsky
Journal:  Brachytherapy       Date:  2016-05-12       Impact factor: 2.362

6.  Long-term outcome of magnetic resonance spectroscopic image-directed dose escalation for prostate brachytherapy.

Authors:  Martin T King; Nicola J Nasser; Nitin Mathur; Gil'ad N Cohen; Marisa A Kollmeier; Jasper Yuen; Hebert A Vargas; Xin Pei; Yoshiya Yamada; Kristen L Zakian; Marco Zaider; Michael J Zelefsky
Journal:  Brachytherapy       Date:  2016-04-20       Impact factor: 2.362

7.  A Population-based Statistical Model for Investigating Heterogeneous Intraprostatic Sensitivity to Radiation Toxicity After 125I Seed Implantation.

Authors:  Kazuma Kobayashi; Naoya Murakami; Kana Takahashi; Koji Inaba; Hiroshi Igaki; Ryuji Hamamoto; Jun Itami
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

8.  Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.

Authors:  Michael C Repka; Shan Guleria; Robyn A Cyr; Thomas M Yung; Harsha Koneru; Leonard N Chen; Siyuan Lei; Brian T Collins; Pranay Krishnan; Simeng Suy; Anatoly Dritschilo; John Lynch; Sean P Collins
Journal:  Front Oncol       Date:  2016-05-18       Impact factor: 6.244

9.  Dynamic Changes in Bladder Morphology Over Time in Cervical Cancer Patients.

Authors:  Fu Jin; Qiang Liu; Huanli Luo; Rui Zhu; Yanhong Mou; Yongzhong Wu; Ying Wang
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

10.  Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy.

Authors:  J C Farris; R T Hughes; C R Steber; T E Craven; B A Frizzell
Journal:  Brachytherapy       Date:  2021-08-02       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.